Business Wire

CA-C3.AI

Share
C3.ai Launches C3.ai COVID-19 Grand Challenge

C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today welcomes data scientists, developers, researchers, and creative thinkers from around the world to participate in the C3.ai COVID-19 Grand Challenge . The competition invites participants to leverage data science techniques in new and innovative ways to generate insights that previously were neither apparent nor achievable.

“The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic,” said Thomas M. Siebel, CEO of C3.ai. “As with the C3.ai COVID-19 Data Lake and the C3.ai Digital Transformation Institute , this initiative will tap our community’s collective IQ to make important strides toward necessary, innovative solutions that will help solve a global crisis.”

What Makes a Great Solution

In response to the acute challenges the world faces, the judging panel will prioritize data science projects that help us understand and mitigate the spread of the virus; improve the response capabilities of the medical community; minimize the impact of this disease on society; and help policymakers navigate responses to COVID-19.

Projects may address, but are not limited to:

  • Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
  • Genome-specific COVID-19 medical protocols, including precision medicine of host responses
  • Biomedical informatics methods for drug design and repurposing
  • Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
  • Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
  • Logistics and optimization analysis for design of public health strategies and interventions
  • Rigorous approaches to designing sampling and testing strategies
  • Data analytics for COVID-19 research harnessing private and sensitive data
  • Improving societal resilience in response to the spread of the COVID-19 pandemic
  • Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics.

Award Criteria

A panel of judges will evaluate submissions on the extent to which they derive insights, leveraging data science techniques (e.g., statistical analyses, AI/ML algorithms, optimization approaches, etc.) that were not obvious before.

  • Pat House, Vice Chairman, C3.ai
  • Mike Callagy, County Manager, County of San Mateo
  • Richard Levin, Board of Directors, C3.ai and Former President Emeritus, Yale University
  • S. Shankar Sastry, Co-Director, C3.ai Digital Transformation Institute and Professor of Electrical Engineering & Computer Sciences, UC Berkeley
  • Zico Kolter, Associate Professor of Computer Science, Carnegie Mellon University

The competition is now open with a registration deadline of Oct. 25 and a submission deadline of Nov. 18, 2020. To learn more about how to submit proposals, please visit https://c3.ai/grand-challenge/ .

By Dec. 9, 2020, C3.ai will announce seven competition winners and award $200,000 in cash prizes to the honorees.

  • Prizes – There will be one Grand Prize of $100,000, two second-place awards of $25,000 each, and four third-place awards of $12,500 each.
  • Publication The winners will have their work published by C3.ai.

C3.ai COVID-19 Data Lake Expands

The C3.ai™ COVID-19 Data Lake , launched in April 2020, continues to expand and now consists of 40 unique datasets, making it the largest unified, federated image of COVID-19 data in the world. Researchers and developers worldwide can access this free, open-source resource to build models, run analytics, develop tools, and more, without the time and effort of data wrangling.

As part of the C3.ai COVID-19 Grand Challenge, applicants will be required to use the C3.ai COVID-19 Data Lake as a resource to generate new and innovative solutions.

The latest datasets to be integrated into the Data Lake include:

For additional information about the C3.ai COVID-19 Data Lake, please visit: https://c3.ai/covid

To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/grand-challenge/ .

About C3.ai

C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI® Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release

-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 11:15:00 CET | Press release

AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on Novem

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 07:16:00 CET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 07:00:00 CET | Press release

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye